What this study adds?
1. A potential atheroprotective agent, ATO, which ameliorates
atherosclerosis by suppressing lipid endocytosis and macrophage
dysfunction.
2. ATO suppresses CD36 expression, and TLR4/NF-κB and NLRP3 inflammasome
activation in macrophages, reducing inflammatory responses.